Skip to main content
Lytix Biopharma AS logo

Lytix Biopharma AS — Investor Relations & Filings

Ticker · LYTIX ISIN · NO0010405780 LEI · 549300NXMIMRSBCDZO71 OL Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2026-03-25 AGM Information
Country NO Norway
Listing OL LYTIX

About Lytix Biopharma AS

https://www.lytixbiopharma.com/

Lytix Biopharma AS is a clinical-stage immuno-oncology company that develops a proprietary platform of oncolytic molecules for cancer treatment. The company's technology is based on molecules designed to selectively target and lyse cancer cell membranes. This process releases a broad spectrum of tumor antigens, which in turn stimulates a patient's immune system to recognize and attack the cancer, effectively turning immunologically "cold" tumors "hot". Its lead drug candidate, ruxotemitide, is being evaluated in clinical trials as a neoadjuvant treatment for various solid tumors, including melanoma and basal cell carcinoma.

Recent filings

Filing Released Lang Actions
Lytix Biopharma AS: Notice of Annual General Meeting on 14 April 2026 - Attachment: Lytix Biopharma - Notice to The Annual General Meeting 2026 Final.pdf
AGM Information Classification · 95% confidence The document is a detailed “Notice of Annual General Meeting” (Innkalling til ordinær generalforsamling) for Lytix Biopharma AS, specifying meeting time, place, agenda items (election of meeting chair, approval of annual accounts and report, dividend distribution, auditor’s remuneration, board authorizations, board and nomination committee elections, remuneration, etc.). It is clearly a solicitation for the AGM, not the actual financial report or minutes. Therefore it is classified as AGM Information (Code: AGM-R).
2026-03-25 English
Lytix Biopharma AS: Notice of Annual General Meeting on 14 April 2026
Proxy Solicitation & Information Statement Classification · 80% confidence The document is clearly a formal notice calling an Annual General Meeting on 14 April 2026. It provides the agenda, instructs shareholders how to register attendance or submit a proxy, and seeks shareholder votes on key items. This aligns with “Proxy Solicitation & Information Statement (PSI)” – materials sent to shareholders to provide meeting information and request votes. It is not the AGM presentation itself nor a full annual report, but the meeting notice and proxy information.
2026-03-25 English
Lytix Biopharma AS: Annual Report for 2025 - Attachment: 2025 Lytix - Annual Report - Final 2023-03-23.pdf
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2025' and contains comprehensive sections including a CEO letter, key highlights, strategic approach, and a Director's Report. It also includes a table of 'KEY FIGURES' providing financial data (operating income, expenses, assets, liabilities) for the 2025 fiscal year. As it is a full annual report containing financial statements and management analysis, it is classified as a 10-K (Annual Report). FY 2025
2026-03-24 English
Lytix Biopharma AS: Annual Report for 2025
Report Publication Announcement Classification · 85% confidence The document is a brief press release announcing that Lytix Biopharma AS has published its Annual Report for 2025, summarizing key highlights and noting that the report is attached and available on the company website. It does not include the full report content but rather directs readers to the report. Under the “menu vs meal” rule, this is a Report Publication Announcement, not the Annual Report itself.
2026-03-24 English
Lytix Biopharma to Present Final Phase II ATLAS-IT-05 Data at the AACR Annual Meeting 2026
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Lytix Biopharma will present clinical trial data at an upcoming medical conference (AACR 2026). It does not contain the actual financial report or the full study results, but rather serves as a corporate announcement regarding future dissemination of information. As it does not fit into specific categories like earnings releases or regulatory filings, and acts as a general corporate update, it is classified under Regulatory Filings (RNS).
2026-03-18 English
Lytix Biopharma Publishes Comprehensive Review on the Transformative Potential of Oncolytic Peptides in Leading Cancer Journal (JITC)
Regulatory Filings Classification · 95% confidence The document is a press release announcing the publication of a scientific review article in a medical journal (JITC). It does not constitute a financial report, regulatory filing, or corporate governance document. As it is a general corporate announcement regarding scientific progress and research publication that does not fit into specific financial categories like 10-K, IR, or ER, it falls under the general regulatory/corporate announcement category.
2026-02-17 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.